Skip to main content
. Author manuscript; available in PMC: 2018 Sep 22.
Published in final edited form as: Obesity (Silver Spring). 2018 Mar 22;26(5):885–894. doi: 10.1002/oby.22166

Figure 4.

Figure 4

Intra-ventromedial hypothalamic (VMH) microinjections of the Melanotan II (MTII) altered mRNA expression of energetic mediators in skeletal muscle (A: medial gastrocnemius; B: quadriceps) in high-and low-capacity runners (HCR, LCR). Beta2: β2 adrenergic receptor; UCP2 and 3: uncoupling protein 2 and 3; PPARa, d, and g: peroxisome proliferator-activated receptor α, δ, and γ; SERCA 1 and 2: sarco/endoplasmic reticulum ATPase 1 and 2; Kir6.1 and 6.2 subunits of the ATP-gated K+ channel, Med1: mediator of RNA polymerase II transcription subunit 1. HCR MTII ≠ LCR MTII in all cases. *within group, MTII treatment significantly different from veh; p<0.05. (N=8-group)